NCT02567708 - A Study to Investigate the Efficacy, Safety, and Tolerability of Repeat Doses of Inhaled GSK2269557 in Adults With Persistent, Uncontrolled Asthma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 1, 2015

Primary Completion Date

September 21, 2016

Study Completion Date

September 28, 2016

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

GSK2269557 DPI

GSK2269557 will be supplied as a lactose blend in a DISKUS DPI with a unit dose strength of 500 mcg. 2 inhalations will be taken every morning before breakfast.

DRUG

Placebo DPI

Placebo will be lactose in a DISKUS DPI. 2 inhalations will be taken every morning before breakfast.

Trial Locations (12)

10119

GSK Investigational Site, Berlin

10717

GSK Investigational Site, Berlin

10787

GSK Investigational Site, Berlin

15562

GSK Investigational Site, Rüdersdorf

23552

GSK Investigational Site, Lübeck

39120

GSK Investigational Site, Magdeburg

60389

GSK Investigational Site, Frankfurt am Main

60596

GSK Investigational Site, Frankfurt am Main

66421

GSK Investigational Site, Homburg

80539

GSK Investigational Site, Munich

04275

GSK Investigational Site, Leipzig

04357

GSK Investigational Site, Leipzig